TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Accuracy of V/Q SPECT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of major and minor strokes
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of intracranial hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: clinically and statistically significant improvements for women with candidiasis, bacterial vaginosis, and trichomoniasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compression quality (CCF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to initiate compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Utilization of hospital-specific maneuvers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative attitudes toward a person with epilepsy
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Iron deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Strength of the illusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand mislocalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in manifest refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in central corneal power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decentration of the ablation zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Final assessment performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confidence scores in ECG interpretation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cure rate at D7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic prescription rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence of sleep disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Clinician and patient-rated clinical effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute Urinary Retention (AUR) episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Need for subsequent BPH-related surgery
Endpoint domain: Adverse events/effects
Primary endpoint: episodes of thrombophlebitis
Endpoint domain: Adverse events/effects
Primary endpoint: Progression of existing hyperostotic abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: New hyperostotic involvement at previously unaffected vertebral levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: myocardial injury evaluated by high sensitive myocardial biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease of bladder bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Decrease of pelvic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease of frequency of voiding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 20-year risk of colon cancer
Endpoint domain: Mortality/survival
Primary endpoint: mortality due to colorectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Mean plasma zinc concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight increments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length increments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of Motion (ROM) of the cervical spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Range of Motion (ROM) of the fifth metacarpophalangeal joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Distance walked after PR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Desaturation measured by pulsoxymetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exacerbation rate per patient per year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee joint space narrowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip joint space narrowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HF hospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incident or worsening nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of STI tasks completed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of drug efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cardiac troponin I level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: beta-Endorphin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Conversion rate to diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Normoglycaemia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in ON time without troublesome dyskinesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in tear osmolarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemodynamic performance of the valves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: estimated gastric volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: LpPLA2 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bone turnover markers (BTM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: early mortality during TB treatment
Endpoint domain: Mortality/survival
Primary endpoint: Reported side-effects at 6-month follow-up
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in PUSH 3.0 scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of emetic symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: combined death/myocardial infarction/target vessel revascularization
Endpoint domain: Mortality/survival
Primary endpoint: troponin release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lung cancer risk associated with pro-SFTPB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: reduction of eosinophil influx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: reduction of eosinophil cationic protein in nasal wash
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: frailty incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriateness of risk perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient's global score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean change from baseline in the CGI-S score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steady‐state geometric mean area under the concentration‐time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: steady‐state concentration 8 hours after drug administration (C(8h,SS))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean trough saquinavir concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Formation of terminal complement complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Formation of C3bc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative patency rate for graft limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Immediate postoperative morbidity and mortality rates
Endpoint domain: Mortality/survival
Primary endpoint: FA of ridge count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FA of pattern discordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: triradii a1 variable
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of asthma attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Respiratory tract infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Reduction in abdominal bloating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency (fn)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in plantar fasciitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of hypophthalmos correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LEFS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: FAAM
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Need for hospitalisation, transplantation, or death
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of excessive sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birth recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Lunch meal intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fullness AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hunger AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone density at the total hip and lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart failure-related events (HFRE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: In-stent relative volumetric obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Likelihood of Ecstasy use
Endpoint domain: Adverse events/effects
Primary endpoint: Reduced inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postexercise Rating of Perceived Exertion (RPE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LH feedforward drive on T secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: T feedback inhibition of LH secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Variation of plasma levodopa concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentrations of the metabolite 3‐O‐methyldopa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall aesthetic appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FFTF rate
Endpoint domain: Mortality/survival
Primary endpoint: long-term urinary discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Assessable patients at end-of-study visit
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Movement pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive T score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pain acceptance and quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Functional limitation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Streptokinase-induced antibody-mediated platelet activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Streptokinase-induced platelet aggregation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative proportion with RTOG grade ≥ 2 toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: VAS score at 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first bolus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bolus in 24h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breakthrough bleeding incidence
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of macroarterial disease
Endpoint domain: Adverse events/effects
Primary endpoint: Hypoalgesia of temporal summation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interrater agreement for pressure ulcer diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Interrater agreement for pressure ulcer grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: average total direct cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: median direct medical cost for routine management
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: median cost of management of recurrent bleeding
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Spatial working memory (SWM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sustained attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: improvement in target limb tremor rating scale (TRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: methacholine challenge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: level of symptoms on the SEC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rates after 6 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Urgent readmission rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MCIC of the PI-NRS
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: MCIC of the QBPDS
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: MCIC for the EQ
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Nasal itching score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal congestion on waking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CMax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of suprapubic pain at 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pain
Primary endpoint: Prevalence of groin pain at 2 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pain
Primary endpoint: Progression-Free Survival (PC) rate
Endpoint domain: Mortality/survival
Primary endpoint: FEV1 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Physical Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients achieving therapeutic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical benefit from active treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrusive trauma memories
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to Tumor Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pathologic complete remission of the primary tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: ACR 20% response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor function of the upper limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric emptying of liquid low calorie meals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Peri-implant crestal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Significant differences in muscular physiological parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects (nausea, vomiting, dysphoria)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of pulmonary cement embolism (PCE)
Endpoint domain: Adverse events/effects
Primary endpoint: Return to normal activities and work
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Physiological indicators
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TRV (Tricuspid Regurgitant Velocity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Readiness to achieve healthy GWG
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Importance to achieve healthy GWG
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Energy consumption from the HD-LV diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: gains in function and dexterity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distortion-product otoacoustic emission levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on interactive test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean LDL-C concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of time in remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of bacteriuria with pyuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum EPA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum DHA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autobiographical Memory Interview change from baseline to 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-week objective anterograde memory scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-week subjective memory scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in AVP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ulcer healing or improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent ulceration or skin deterioration
Endpoint domain: Adverse events/effects
Primary endpoint: Mean number of active T2 lesions per patient per scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean assessment scores for CR vs. PR at 1-week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge decay for the 12-week period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance on SBA-related vs. unrelated questions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h mean ambulatory SBP increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 24-h mean ambulatory DBP increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resistance to antibiotics
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients asleep at 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of tranquillisation/sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TXB2 levels in maternal blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TXB2 levels in cord blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-keto-PGF1alpha levels in maternal blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes